| Prev Close | 42.85 |
| Open | 46.15 |
| Day Low/High | 45.31 / 47.71 |
| 52 Wk Low/High | 18.93 / 59.25 |
| Volume | 7.32M |
Canopy Growth Corporation (CGC)
46.14
3.29
7.68
NYSE
| Exchange | NYSE |
| Shares Outstanding | 342.98B |
| Market Cap | 14.30B |
| Div & Yield | N.A. (N.A) |
Cannabis Could Disrupt the Lucrative Market for Painkillers
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
Cannabis-Related Products Could Be Your Dog's Best Friend (And Your Portfolio's)
Expert says weed-related products for pets could become a $55 billion-a-year business.
Canopy Growth CEO: Traditional Firms Will See They Must Get Into Legal Cannabis
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
Despite Taking Some Weed, Constellation Brands Charts Are Still Bearish
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
Canopy Growth Could See New Highs: Here's How to Trade This Hot Cannabis Stock
A look at CGC's charts and our latest strategy.
Canopy Growth CEO Sees Dot-Com-Like Bust for Many Weed Stocks
'There's too much hype too soon,' Canopy Growth chief Bruce Linton says.
Jim Cramer: Reefer Madness
Tilray's a disruptive company for many industries.
If You Must Trade Tilray, Use This Options Play: Market Recon
Covered calls may be the best bet -- or wait for a dip.
Tilray Closes up 38% After Wild Trading Day
Shares were up 94% and down 2.3% in the same session.
Tilray and Other Cannabis Firms Have Even More Catalysts on the Horizon
Canadian marijuana legalization and U.S. approval of industrial hemp are coming.
Jim Cramer: The Tilray Short Squeeze
Cannabis companies should be taking advantage of the mania to raise money.
Tilray's Sales Are Irrelevant and Its Charts Don't Matter
Don't try to explain the stock's meteoric rise on a fundamental or technical basis, because it defies both.
How to Play Tilray With Options
A so-called 'ratio-put spread' looks good here.
Play Tilray Using a 'Ratio-Put Spread'
This options trade combines some upside with a chance to buy TLRY at a decent price.
Tilray Surges Over 50% Wednesday Morning, Punishing Short-Sellers
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
Experts Are High on Cannabis Stocks' 2019 Prospects
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
Aurora Cannabis Shares Surge as Coca-Cola Confirms CBD Interest
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
Coke's Flirtation with Cannabis Reaffirms What We Already Know
The latest reports about Coke looking into cannabis confirms a broader industry trend.
Jim Cramer: Be Cautious Before You Invest in the Budding Cannabis Industry
You don't want your money to go up in smoke.
Cannabis for Traders, Cannabis for Investors: Market Recon
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Vape Pen Growth Is Going to Explode
Here are 4 stocks to buy to invest in this trend.
Mainstream Research Just Doesn't Get Canopy Growth
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.
Canada's Hexo Pursues Additional JV Cannabis Deals After Molson
Hexo is pursuing joint ventures in cosmetics, health care, candy, edibles, and vape companies.
2 Big Themes Are Driving Chaotic Market Action
The underlying action, particularly the weakness in the technology sector, is reason for concern.
Advisors, Analysts Brush Off Nike Controversy, Say Selloff Is Short-Lived
Analysts and advisors stand by Nike as NFL.
Will Investors Be Ready to Digest All the New Cannabis Stocks?
Several cannabis companies are planning to go public this fall.
Tilray Feeds Deal-Making Speculation on Analyst Call
Tilray reported a 95% jump in second-quarter revenue to $9.7 million, ahead of the Wall Street estimate of $9 million, in its first earnings release since it went public on July 19.
What If Canopy Growth Is Getting Too High?
This is simply a short-term thesis that the cannabis rally will cool this week.
Low Volume and Seasonality Is No Reason to Fight This Stock Market Uptrend
Seasonality hasn't mattered in a number or years so why should light volume new highs be an issue?
Tilray Offers Test of Transitioning to Recreational Cannabis Use in Canada
The Nasdaq-listed provider of medical marijuana will compete with other firms as Canada opens itself to general adult use of marijuana this fall.
